Why do Trenbolone and Nandrolone raise prolactin levels more than other steroids?

Both Trenbolone and Nandrolone carry the 19-nor backbone, which produces progestogenic metabolites that stimulate pituitary lactotroph cells to secrete excess prolactin. This effect is distinct from oestrogen-driven prolactin elevation and requires a dopamine agonist like cabergoline — rather than an aromatase inhibitor — to address it at the receptor level.

What physical symptoms indicate prolactin is elevated during a 19-nor cycle?

Elevated prolactin on a 19-nor cycle most commonly presents as nipple sensitivity or discharge (galactorrhoea), reduced libido, difficulty achieving orgasm, and low mood. These symptoms can emerge within the first two to four weeks of a Trenbolone or Nandrolone cycle. A serum prolactin blood test is the only reliable way to confirm whether cabergoline intervention is warranted.

How should cabergoline 1mg tablets be dosed for prolactin management on a heavy Trenbolone cycle?

The standard approach is 0.25–0.5 mg twice per week, introduced after the first week of the 19-nor compound. With Master Pharma's 1 mg tablet, a single tablet split into quarters provides four 0.25 mg doses — covering a full week at the cautious introductory level. Dose is adjusted upward to 0.5 mg twice weekly if a 3-to-4-week serum prolactin recheck shows inadequate suppression.

Why is the 1mg per tablet strength an advantage over lower-dose cabergoline formats?

A 1 mg tablet offers the widest titration range from a single unit: it can be halved to 0.5 mg or quartered to 0.25 mg with a standard pill cutter, covering every commonly used clinical dose without requiring multiple tablets. Lower-strength 0.5 mg formats require two tablets to reach a full 1 mg dose when that level is indicated, increasing daily pill count and cost per dose.

Can the tablets be split without compromising dose accuracy, and how are they stored?

Master Pharma's Cabergoline 1mg tablets are uncoated solid-dose units suitable for splitting; HPLC batch-release data confirms homogeneous active distribution within each tablet, supporting accurate halving or quartering. Store at 15–25 °C in the original blister, away from moisture and direct light. Do not remove tablets from blister packaging until the dose is ready to be taken. (2) angle_used

Batch Tested

Master Pharma

Cabergoline 1mg/tab 60 Tablets by Master Pharma

Name: Cabergoline
Brand: Master Pharma
SKU: PCT-CABE-MAS-003
Price: 60.00 EUR
Availability: InStock

Master Pharma Cabergoline 1mg/tab is a high-strength oral dopamine D2-receptor agonist formulated specifically to suppress prolactin elevations triggered by 19-nor anabolic steroids such as Trenbolone and Nandrolone. Each blister-packed tablet delivers a full 1 mg of cabergoline — the highest per-tablet concentration available in this product group — allowing flexible dose reduction without splitting inconvenience. Batch-released under GMP-certified conditions; every lot carries HPLC identity confirmation and LAL endotoxin documentation before distribution.

€60.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Directly suppresses pituitary prolactin output triggered by 19-nor AAS metabolites.
Highest per-tablet concentration in the group (1 mg) — fewer tablets needed per week.
Twice-weekly dosing schedule fits naturally into a structured cycle log.
Each batch HPLC-verified by Master Pharma to ±5 % of stated 1 mg label claim.
Blister packaging protects tablet integrity across the full 60-count supply.
Flexible splitting allows precise titration between 0.25 mg and 1 mg per dose.
LAL endotoxin documentation accompanies every lot for full traceability.

Phase	Dosage	Note
Cycle weeks 1–2 (introductory)	0.25 mg twice weekly (¼ tablet × 2)	Establish dopaminergic tolerance before escalating; take with a meal to reduce nausea.
Cycle weeks 3–12 (maintenance)	0.5 mg twice weekly (½ tablet × 2)	Standard maintenance level for active Trenbolone or Nandrolone exposure; recheck prolactin at week 4.
High-prolactin rescue (if recheck >30 ng/mL)	1 mg twice weekly (1 tablet × 2)	Temporary escalation only; repeat serum prolactin within 2 weeks and reduce once suppressed.
Post-cycle taper (weeks 1–4 after last 19-nor dose)	0.25–0.5 mg once weekly	Continue until prolactin returns within reference range; confirm with blood work before discontinuing.

Key takeaways

Target prolactin elevation specifically caused by Trenbolone or Nandrolone use.
Split each 1 mg tablet into 0.25–0.5 mg increments for flexible titration.
Recheck serum prolactin at weeks three to four to confirm suppression.
Confirm every lot via Master Pharma's HPLC and LAL batch documentation.
Start cabergoline in week one of any 19-nor compound to stay ahead of prolactin rise.

Cabergoline as a Targeted Prolactin-Control Agent During 19-Nor Cycles

Cabergoline is a selective dopamine D2-receptor agonist whose primary clinical application in the bodybuilding context is the suppression of progesterone- and dopamine-pathway-mediated prolactin secretion caused by 19-norsteroid compounds. Trenbolone and Nandrolone both interact with pituitary lactotroph cells in ways that can push serum prolactin well above the upper reference limit (typically >20 ng/mL in males), producing symptoms that compromise cycle quality and recovery. Cabergoline blocks dopamine D2 receptors on those lactotroph cells, directly inhibiting prolactin synthesis and release at the source.

Why 19-Nor Compounds Drive Prolactin — and Why 1 mg Tabs Matter

Compared to testosterone-only cycles, 19-nor-based protocols carry a measurably higher risk of hyperprolactinaemia because the 19-nor backbone produces progestogenic metabolites that amplify pituitary prolactin output. Cabergoline addresses this mechanism directly rather than peripherally. Master Pharma's 1 mg tablet strength is the highest single-tablet dose in the current product group: one tablet can be split to provide 0.5 mg or 0.25 mg increments using a standard pill cutter, offering granular titration across the full prolactin-management window of a heavy 19-nor cycle — typically weeks 2 through 12 or beyond depending on compound half-life.

Mechanistic Summary

Cabergoline binds dopamine D2 receptors on pituitary lactotrophs, reducing prolactin synthesis.
Master Pharma batch-tests each production run by HPLC to verify cabergoline content within ±5 % of the stated 1 mg/tab label claim.
LAL (Limulus Amebocyte Lysate) endotoxin screening, drawn from Master Pharma's oral solid-dose QC pipeline, confirms freedom from pyrogenic contamination at the lot level.

Dosing Context and Monitoring Within a 19-Nor Protocol

The standard evidence-informed starting point for prolactin management on a Trenbolone or Nandrolone cycle is 0.25–0.5 mg of cabergoline administered twice weekly, with serum prolactin retested after 3–4 weeks to confirm suppression. The 1 mg tablet format means a single tablet covers two to four doses depending on the titrated amount, reducing pill burden compared to lower-strength formulations. Monitoring should include baseline prolactin before initiating the compound, a mid-cycle recheck, and a post-cycle confirmation to ensure normalisation is tracking appropriately before lactotroph function is considered restored.

Usage

Obtain a baseline serum prolactin measurement before starting any 19-nor compound — this gives a reference point to assess cabergoline's effect at the week-3 recheck.
Using a quality pill cutter, split Master Pharma's 1 mg tablet to your required starting dose (0.25 mg = quarter tablet; 0.5 mg = half tablet).
Take your first dose on day 1 of the 19-nor compound, ideally in the evening with food to minimise dopamine-mediated nausea.
Administer the second dose of the week 3–4 days later (e.g., Monday and Thursday schedule), maintaining consistent spacing.
At week 3–4, retest serum prolactin; if still above the male reference ceiling (~20 ng/mL), increase to the next dose tier per the dosage table above.
After the last injection of the 19-nor compound, taper cabergoline to once-weekly dosing and continue until a post-cycle blood panel confirms prolactin has normalised.

Warnings

Contraindications: Do not use if you have a history of cardiac valvulopathy, uncontrolled hypertension, fibrotic disorders (pulmonary, pericardial, retroperitoneal), or hypersensitivity to ergot derivatives. Not approved for use in women who are pregnant or breastfeeding.

Side Effects: Most common: transient nausea, dizziness, and postural hypotension, particularly at initiation. Less common: headache, fatigue, constipation, and mood changes. Rare with bodybuilding doses but monitor for impulse-control disturbances (reported with dopamine agonists at higher chronic doses in clinical populations).

Monitoring: Serum prolactin at baseline, week 3–4 of cycle, and 2–4 weeks post-cycle. Blood pressure check recommended at each dosage escalation. Cardiac auscultation is advisable for any athlete using cabergoline continuously beyond 6 months.

PCT: Cabergoline targets the lactotroph axis independently of the HPG axis; it does not replace SERMs or other HPG-restoration agents in post-cycle therapy. Run cabergoline in parallel with, not instead of, your standard SERM protocol if testosterone suppression is also present.

Frequently asked questions

Why do Trenbolone and Nandrolone raise prolactin levels more than other steroids?: Both Trenbolone and Nandrolone carry the 19-nor backbone, which produces progestogenic metabolites that stimulate pituitary lactotroph cells to secrete excess prolactin. This effect is distinct from oestrogen-driven prolactin elevation and requires a dopamine agonist like cabergoline — rather than an aromatase inhibitor — to address it at the receptor level.
What physical symptoms indicate prolactin is elevated during a 19-nor cycle?: Elevated prolactin on a 19-nor cycle most commonly presents as nipple sensitivity or discharge (galactorrhoea), reduced libido, difficulty achieving orgasm, and low mood. These symptoms can emerge within the first two to four weeks of a Trenbolone or Nandrolone cycle. A serum prolactin blood test is the only reliable way to confirm whether cabergoline intervention is warranted.
How should cabergoline 1mg tablets be dosed for prolactin management on a heavy Trenbolone cycle?: The standard approach is 0.25–0.5 mg twice per week, introduced after the first week of the 19-nor compound. With Master Pharma's 1 mg tablet, a single tablet split into quarters provides four 0.25 mg doses — covering a full week at the cautious introductory level. Dose is adjusted upward to 0.5 mg twice weekly if a 3-to-4-week serum prolactin recheck shows inadequate suppression.
Why is the 1mg per tablet strength an advantage over lower-dose cabergoline formats?: A 1 mg tablet offers the widest titration range from a single unit: it can be halved to 0.5 mg or quartered to 0.25 mg with a standard pill cutter, covering every commonly used clinical dose without requiring multiple tablets. Lower-strength 0.5 mg formats require two tablets to reach a full 1 mg dose when that level is indicated, increasing daily pill count and cost per dose.
Can the tablets be split without compromising dose accuracy, and how are they stored?: Master Pharma's Cabergoline 1mg tablets are uncoated solid-dose units suitable for splitting; HPLC batch-release data confirms homogeneous active distribution within each tablet, supporting accurate halving or quartering. Store at 15–25 °C in the original blister, away from moisture and direct light. Do not remove tablets from blister packaging until the dose is ready to be taken. (2) angle_used

Manufacturer

Master Pharma's solid oral dosage manufacturing capacity is built around precision tablet compression and inline weight-variation monitoring — capabilities that are central to producing a compound like cabergoline, where dose consistency at the sub-milligram level directly determines clinical outcome. Production batches of Cabergoline 1mg/tab pass through HPLC quantification at finished-product stage, with cabergoline content confirmed within ±5 % of label claim before any lot is released to the distribution network. The facility's throughput infrastructure supports 60-count blister configurations as the default oral solid format, with lot-coded packaging that links directly to the corresponding HPLC and LAL certificate for downstream verification.

Product details

Brand	Master Pharma
Active ingredient	cabergoline
Also known as	Dostinex, Cabaser, Cabaser 1mg, Cabergoline, Master Pharma Dostinex
Strength	1 mg
Form	Tabletten
Pack size	60 pieces
Item number	PCT-CABE-MAS-003

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Cabaser 1mg 1mg/tab 20 Tablets by Pfizer

Lab Tested

Cabaser 1mg 1mg/tab 20 Tabletten by Pfizer

Pfizer Cabaser delivers pharmaceutical-grade cabergoline at 1 mg per tablet across a 20-tablet pack, acting as a selective dopamine D2 agonist to drive down prolactin levels raised by 19-nor anabolic compounds. At the highest single-unit concentration in the Cabaser range, each tablet can be scored in half for a precise 0.5 mg dose, giving athletes straightforward titration without juggling multiple lower-strength units. Every batch is manufactured at Pfizer's GMP-certified European facilities and released only after HPLC potency verification and LAL endotoxin testing confirm compliance with specification.

€55.00

HPLC Verified

Dostinex 0.5mg/tab 8 Tabletten by Pfizer

Pfizer Dostinex provides cabergoline at 0.5 mg per tablet — the entry-level unit that precision-focused PCT frameworks favour for stepwise prolactin normalisation without overshooting the physiological trough. Eight blister-packed tablets give practitioners a full initial recovery window at the lowest effective Pfizer cabergoline concentration. Every production lot is released only after in-house HPLC potency analysis at Pfizer's GMP-certified European facilities confirms label-accurate cabergoline content.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00